Nutra Pharma Reports 63.4% Revenue Growth but Faces Net Loss in Q2 2025

Nutra Pharma Corp. reported its financial results for the second quarter of 2025, revealing a net sales figure of $84,532 for the three months ending June 30, compared to $51,710 for the same period in 2024, marking an increase of 63.4%. For the first half of 2025, net sales reached $158,506, up from $89,442 in the prior year, reflecting a growth of 77.2%. Despite this increase in revenue, the company reported a net loss of $369,577 for the second quarter, a reversal from a loss of $367,139 in the same quarter of the previous year. The accumulated deficit as of June 30, 2025, stood at $77,266,483, up from $76,231,137 at the end of 2024.

The company’s operating expenses also rose significantly, totaling $366,157 for the second quarter of 2025, compared to $274,338 in the same quarter of 2024, representing a 33.4% increase. This rise in expenses contributed to a loss from operations of $290,529 for the quarter, compared to a loss of $219,493 in the prior year. The increase in operating expenses was attributed to higher selling, general, and administrative costs, which totaled $784,307 for the first half of 2025, up from $604,844 in the same period of 2024.

Nutra Pharma's balance sheet showed total assets of $859,068 as of June 30, 2025, a significant increase from $599,495 at the end of 2024. Current assets rose to $665,128, driven by increases in cash, accounts receivable, and prepaid expenses. However, total liabilities also increased to $16,692,328 from $15,407,409, resulting in a stockholders' deficit of $15,833,260, compared to $14,807,914 at the end of the previous fiscal year. The company continues to face challenges with a working capital deficit of $15,888,753 and substantial debt obligations.

In terms of operational developments, Nutra Pharma has continued to focus on its product lines, which include pain relief medications such as Cobroxin® and Nyloxin®. The company has also been exploring avenues for geographic expansion and product adoption, although specific metrics on customer counts or market share were not disclosed in the filing. The company’s common stock is currently listed on the OTC Market Group’s Expert Market, which limits its ability to raise capital. Nutra Pharma indicated that it will need to secure additional financing to sustain operations and execute its business plan, as current sales levels are insufficient to cover operational costs.

Looking ahead, Nutra Pharma's management expressed uncertainty regarding its ability to continue as a going concern without securing additional financing. The company is actively seeking funding through debt and equity sources to support its operations and growth strategy. However, the filing noted that there is substantial doubt about the company's ability to achieve profitable operations in the near term, which could impact its future viability.